355 related articles for article (PubMed ID: 22913770)
1. PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers.
Ivens IA; Baumann A; McDonald TA; Humphries TJ; Michaels LA; Mathew P
Haemophilia; 2013 Jan; 19(1):11-20. PubMed ID: 22913770
[TBL] [Abstract][Full Text] [Related]
2. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
Mahdi AJ; Obaji SG; Collins PW
Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
[TBL] [Abstract][Full Text] [Related]
3. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.
Collins P; Chalmers E; Chowdary P; Keeling D; Mathias M; O'Donnell J; Pasi KJ; Rangarajan S; Thomas A
Haemophilia; 2016 Jul; 22(4):487-98. PubMed ID: 27311929
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A.
Gu JM; Ramsey P; Evans V; Tang L; Apeler H; Leong L; Murphy JE; Laux V; Myles T
Haemophilia; 2014 Jul; 20(4):593-600. PubMed ID: 24471985
[TBL] [Abstract][Full Text] [Related]
5. Progress in the treatment of bleeding disorders.
Bergman GE
Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
[TBL] [Abstract][Full Text] [Related]
6. Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates.
von Mackensen S; Kalnins W; Krucker J; Weiss J; Miesbach W; Albisetti M; Pabinger I; Oldenburg J
Haemophilia; 2017 Jul; 23(4):566-574. PubMed ID: 28370896
[TBL] [Abstract][Full Text] [Related]
7. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
[TBL] [Abstract][Full Text] [Related]
8. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
Björkman S; Folkesson A; Berntorp E
Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
[TBL] [Abstract][Full Text] [Related]
9. Changing paradigm of prophylaxis with longer acting factor concentrates.
Carcao M
Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
[TBL] [Abstract][Full Text] [Related]
10. Longer-acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issue.
Di Minno G; Cerbone AM; Coppola A; Cimino E; Di Capua M; Pamparana F; Tufano A; Di Minno MN
Haemophilia; 2010 Jan; 16 Suppl 1():2-6. PubMed ID: 20059562
[TBL] [Abstract][Full Text] [Related]
11. New products for the treatment of haemophilia.
Laffan M
Br J Haematol; 2016 Jan; 172(1):23-31. PubMed ID: 26456702
[TBL] [Abstract][Full Text] [Related]
12. Extended half-life clotting factor concentrates: results from published clinical trials.
Young G; Mahlangu JN
Haemophilia; 2016 Jul; 22 Suppl 5():25-30. PubMed ID: 27405672
[TBL] [Abstract][Full Text] [Related]
13. The natural history of mild haemophilia: a 30-year single centre experience.
Tagliaferri A; Di Perna C; Riccardi F; Pattacini C; Rivolta GF; Franchini M
Haemophilia; 2012 Mar; 18(2):166-74. PubMed ID: 21771207
[TBL] [Abstract][Full Text] [Related]
14. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
[TBL] [Abstract][Full Text] [Related]
16. Importance of pharmacokinetics in the management of hemophilia.
Barnes C
Pediatr Blood Cancer; 2013; 60 Suppl 1():S27-9. PubMed ID: 23109436
[TBL] [Abstract][Full Text] [Related]
17. A comparison of coagulation factor replacement with and without prednisolone in the treatment of haematuria in haemophilia and Christmas disease.
Rizza CR; Kernoff PB; Matthews JM; McLennan CR; Rainsford SG
Thromb Haemost; 1977 Feb; 37(1):86-90. PubMed ID: 320712
[TBL] [Abstract][Full Text] [Related]
18. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.
Wang C; Young G
Haemophilia; 2018 May; 24(3):414-419. PubMed ID: 29405496
[TBL] [Abstract][Full Text] [Related]
19. How to manage invasive procedures in children with haemophilia.
Ljung RC; Knobe K
Br J Haematol; 2012 Jun; 157(5):519-28. PubMed ID: 22390160
[TBL] [Abstract][Full Text] [Related]
20. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
Mathias M; Khair K; Hann I; Liesner R
Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
